Alzheimer Disease

USMLE Step 1 trap: Confuses the protein composition of neurofibrillary tangles (tau) with amyloid plaques (Aβ). Neurofibrillary tangles are composed of hyperphosphorylated tau protein, while senile plaques contain amyloid-beta (Aβ42) derived from APP cleavage.

Alzheimer disease is the most common cause of dementia and a perennial high-yield topic on USMLE Step 1. The exam tests it from three angles simultaneously: the histopathology (what you'd see under the microscope and on gross exam), the genetics (who gets it and why), and the clinical presentation (how it progresses and what drugs target it). What makes this topic tricky isn't any single fact — it's that students memorize isolated details without connecting them into a mechanistic story, which is exactly what the exam exploits.

The two biggest traps are the amyloid/tau mix-up and the APOE4 misconception. Many students conflate neurofibrillary tangles with amyloid plaques, and separately, they treat APOE4 like an autosomal dominant mutation when it's actually just a risk allele. Step 1 will absolutely give you a vignette where you have to distinguish these, so the distinction needs to be reflexive. The cholinergic deficit is another classic trick — Alzheimer is an acetylcholine problem (nucleus basalis of Meynert), not a dopamine problem like Parkinson's.

On USMLE Step 1, Alzheimer questions often come as passage-based vignettes describing a patient's cognitive trajectory or showing a biopsy image, then asking you to identify the underlying protein, gene, or mechanism. You need to be able to move from clinical scenario → pathophysiology → drug target fluidly. The Down syndrome connection (trisomy 21 → extra APP copies → early Aβ accumulation) is a frequently tested gap that rewards students who understand the mechanism rather than just the association.

From real student decks

92%have cards covering this topic

78%have mature cards

1.0median lapses in 14 days

Well-covered in most decks — the challenge is retention, not exposure.

Common misconceptions

Common mistake

Wrong: Neurofibrillary tangles are composed of amyloid-beta.

Right: Neurofibrillary tangles are composed of hyperphosphorylated tau protein, while senile plaques contain amyloid-beta (Aβ42) derived from APP cleavage.

Neurofibrillary tangles are made of hyperphosphorylated tau protein, not amyloid-beta — these are two completely separate pathological lesions. Amyloid-beta (specifically Aβ42) accumulates extracellularly as senile plaques and is derived from abnormal cleavage of APP. Tau normally stabilizes microtubules; when it becomes hyperphosphorylated, it detaches and forms intracellular tangles that destroy neurons from the inside. Keep them straight: plaques = amyloid outside, tangles = tau inside.

Common mistake

Wrong: APOE4 causes Alzheimer disease with autosomal dominant inheritance.

Right: APOE4 is a risk factor (not a deterministic mutation) for late-onset sporadic Alzheimer disease; early-onset familial AD is caused by autosomal dominant mutations in APP, PSEN1, or PSEN2.

APOE4 is a susceptibility allele that increases risk for late-onset Alzheimer disease, but it does not cause disease with certainty — someone can have two copies of APOE4 and never develop Alzheimer's. Early-onset familial AD is a completely different situation: mutations in APP (chromosome 21), PSEN1 (chromosome 14), or PSEN2 (chromosome 1) are autosomal dominant and nearly always cause disease. When a Step 1 vignette says 'family history of early dementia in multiple generations,' think APP/PSEN mutations, not APOE4.

Common mistake

Wrong: Alzheimer disease is primarily a dopamine deficiency disorder.

Right: Alzheimer disease is characterized by loss of cholinergic neurons from the nucleus basalis of Meynert, resulting in acetylcholine deficiency.

Alzheimer disease targets cholinergic neurons, specifically in the nucleus basalis of Meynert, leading to an acetylcholine deficiency — this is why cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are the first-line treatment. Dopamine depletion is the hallmark of Parkinson disease, not Alzheimer's. Confusing these two leads to wrong drug selection on clinical vignettes, so anchor it: Alzheimer = ACh deficit = cholinesterase inhibitor.

Common mistake

Gap: Unaware that Down syndrome patients develop early Alzheimer pathology due to APP gene triplication

Trisomy 21 (Down syndrome) patients have three copies of the APP gene on chromosome 21 and almost universally develop Alzheimer-type pathology by age 40.

Down syndrome patients carry three copies of chromosome 21, which houses the APP gene encoding amyloid precursor protein. Three copies of APP means three times the substrate for Aβ production, so these patients accumulate amyloid plaques and neurofibrillary tangles starting in early adulthood and almost universally have Alzheimer-type pathology by age 40. This is a direct mechanistic link — it's not just an association — and it reinforces why APP is central to Alzheimer pathogenesis.

Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →

Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

Identify the specific histologic findings in Alzheimer disease — senile plaques (extracellular amyloid-beta/Aβ42) and neurofibrillary tangles (intracellular hyperphosphorylated tau) — and know the gross finding of hippocampal and cortical atrophy plus the neurochemical finding of acetylcholine deficiency from nucleus basalis of Meynert degeneration.
Distinguish between early-onset familial Alzheimer disease (autosomal dominant mutations in APP, PSEN1, or PSEN2) and late-onset sporadic Alzheimer disease (associated with the APOE4 risk allele, which is NOT a deterministic mutation and does NOT follow Mendelian inheritance).
Trace the clinical progression of Alzheimer disease from early short-term memory loss to global cognitive decline, and know the diagnostic tools (MMSE, MoCA) and treatments (cholinesterase inhibitors like donepezil for mild-moderate; memantine for moderate-severe) that target the underlying cholinergic and glutamate pathway deficits.

Can you avoid these mistakes?

A 58-year-old man develops progressive memory loss. His father and paternal aunt both had dementia in their 50s. Genetic testing reveals a mutation in PSEN1. What is the inheritance pattern of this form of Alzheimer disease, and how does it differ mechanistically from the role of APOE4?

A brain biopsy from an Alzheimer patient shows two distinct lesions under silver stain. One is extracellular and the other is intracellular. What protein composes each lesion, where does each protein come from, and what enzyme is responsible for generating the pathologic extracellular fragment?

A 35-year-old patient with Down syndrome begins showing signs of dementia. A family member asks why this happened so early. What is the chromosomal explanation, and which specific gene on that chromosome drives the pathology?

A patient with moderate Alzheimer disease is started on a new medication targeting a different receptor than donepezil. Which neurotransmitter system does this second drug act on, what is its mechanism, and at what stage of disease is it typically added?

Alzheimer Disease

Common misconceptions

What the exam tests

Can you avoid these mistakes?

Related topics